{Reference Type}: Case Reports
{Title}: Dupilumab in a patient with severe asthma and glucocorticoid hypersensitivity: a case report.
{Author}: Handa H;Tsuruoka H;Kinoshita K;Mineshita M;
{Journal}: J Int Med Res
{Volume}: 51
{Issue}: 8
{Year}: 2023 Aug
{Factor}: 1.573
{DOI}: 10.1177/03000605231193922
{Abstract}: Recently, several biologics have been approved for the treatment of severe asthma. Dupilumab, a biologic used to treat severe asthma, is a monoclonal antibody targeting interleukin-4 and interleukin-13. In the present case, inhaled corticosteroid-induced glucocorticoid hypersensitivity was suspected, and the administration of omalizumab and mepolizumab had no beneficial effects. Subsequently, we switched to dupilumab therapy, which produced better effectiveness. Therefore, when a biologic agent proves ineffective, changing to another suitable biologic agent should be considered.